NO20052515L - Frigjoringskontrollerte sammensetninger - Google Patents

Frigjoringskontrollerte sammensetninger

Info

Publication number
NO20052515L
NO20052515L NO20052515A NO20052515A NO20052515L NO 20052515 L NO20052515 L NO 20052515L NO 20052515 A NO20052515 A NO 20052515A NO 20052515 A NO20052515 A NO 20052515A NO 20052515 L NO20052515 L NO 20052515L
Authority
NO
Norway
Prior art keywords
release
matrix
agent
release controlled
core
Prior art date
Application number
NO20052515A
Other languages
English (en)
Other versions
NO20052515D0 (no
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Quzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Original Assignee
Labopharm Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Europe Ltd filed Critical Labopharm Europe Ltd
Publication of NO20052515D0 publication Critical patent/NO20052515D0/no
Publication of NO20052515L publication Critical patent/NO20052515L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En fast doseringsformulering med en kjerne med et farmakologisk middel dispergert i en første frigjøringskontrollert matrise hvorfra frigjøringen av middelet skjer relativt langsomt; og et belegg dannet over kjernen og med et middel dispergert i en andre frigjøringskontrollert matrise hvorfra frigjøringen av middelet skjer relativt raskt. Den første matrisen kan være en kryssbundet amyloserik stivelse og den andre matrisen kan være en blanding av polyvinylacetat og polyvinylpyrrolidon.
NO20052515A 2002-10-25 2005-05-25 Frigjoringskontrollerte sammensetninger NO20052515L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US50906202P 2002-10-25 2002-10-25
PCT/CA2003/001637 WO2004038428A2 (en) 2002-10-25 2003-10-27 Controlled-release compositions

Publications (2)

Publication Number Publication Date
NO20052515D0 NO20052515D0 (no) 2005-05-25
NO20052515L true NO20052515L (no) 2005-05-25

Family

ID=34976756

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052515A NO20052515L (no) 2002-10-25 2005-05-25 Frigjoringskontrollerte sammensetninger

Country Status (19)

Country Link
EP (1) EP1558935B1 (no)
JP (1) JP2006507276A (no)
KR (1) KR101120729B1 (no)
AT (1) ATE400819T1 (no)
AU (1) AU2003275854B9 (no)
BR (1) BR0315657A (no)
CA (1) CA2503361C (no)
DE (1) DE60322091D1 (no)
DK (1) DK1558935T3 (no)
EC (1) ECSP055748A (no)
ES (1) ES2310686T3 (no)
HK (1) HK1086475A1 (no)
MX (1) MXPA05004410A (no)
NO (1) NO20052515L (no)
NZ (1) NZ539869A (no)
PT (1) PT1558935E (no)
RU (1) RU2333745C2 (no)
SI (1) SI1558935T1 (no)
WO (1) WO2004038428A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
EP1917000A2 (en) 2005-07-07 2008-05-07 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
PL1931346T3 (pl) 2005-09-09 2013-01-31 Angelini Labopharm Llc Kompozycja trazodonu do podawania raz na dobę
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US20090169617A1 (en) * 2006-04-26 2009-07-02 Panagiotis Keramidas Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
CN100387988C (zh) * 2006-07-25 2008-05-14 山东省医药工业研究所 一种布洛伪麻那敏复方制剂的含量检测方法
WO2008095263A1 (en) 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2203166B1 (en) 2007-10-16 2015-05-06 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
NZ589742A (en) 2008-05-27 2012-06-29 Univ Melbourne Methods of treating mammals with eustachian tube dysfunctions with betahistine
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US20130039864A1 (en) * 2010-04-23 2013-02-14 Francois Ravenelle Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2673818C2 (ru) 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
AU8293498A (en) * 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
KR100507946B1 (ko) * 2001-01-31 2005-08-17 룀 게엠베하 운트 콤파니 카게 상이하게 피복된 펠렛 형태를 두 가지 이상 포함하는 다중 입상형 약제

Also Published As

Publication number Publication date
EP1558935B1 (en) 2008-07-09
RU2005115883A (ru) 2006-01-27
RU2333745C2 (ru) 2008-09-20
CA2503361C (en) 2012-02-28
KR20050088281A (ko) 2005-09-05
DK1558935T3 (da) 2008-11-17
WO2004038428A2 (en) 2004-05-06
ATE400819T1 (de) 2008-07-15
AU2003275854B9 (en) 2009-08-27
ECSP055748A (es) 2005-08-11
AU2003275854A1 (en) 2004-05-13
AU2003275854B2 (en) 2008-09-11
CA2503361A1 (en) 2004-05-06
DE60322091D1 (de) 2008-08-21
HK1086475A1 (en) 2006-09-22
NO20052515D0 (no) 2005-05-25
KR101120729B1 (ko) 2012-04-23
SI1558935T1 (sl) 2008-12-31
WO2004038428A3 (en) 2005-06-09
EP1558935A2 (en) 2005-08-03
ES2310686T3 (es) 2009-01-16
MXPA05004410A (es) 2005-11-23
JP2006507276A (ja) 2006-03-02
PT1558935E (pt) 2008-10-16
BR0315657A (pt) 2005-09-13
NZ539869A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
NO20052515L (no) Frigjoringskontrollerte sammensetninger
ME00482B (me) Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje
CO4700474A1 (es) Formulacion oral de 2-metil-tieno-benzodiacepina
ME00391B (me) Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
MX9707585A (es) Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
RS54929B1 (sr) Formulacija i metod obložene tablete
TWI235068B (en) Sustained-release pharmaceutical composition
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
ATE455538T1 (de) Retardtabletten mit hydromorphon
ZA200509477B (en) Delayed release tablet with defined core geometry
TR200102880T2 (tr) Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
AR099437A2 (es) Matriz para la liberación sostenida, invariable e independiente de compuestos activos
ATE185266T1 (de) Schnell auflösende orale darreichungsform
MY142195A (en) Controlled-release compositions
UA86929C2 (ru) Композиция с контролируемым высвобождением
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
BRPI0315657B8 (pt) formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application